Correction: Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients

• Marion Alcantara,
• Marion Chevrier,
• Fabrice Jardin,
• Anna Schmitt,
• Caroline Houillier,
• Lucie Oberic,
• Olivier Chinot,
• Franck Morschhauser,
• Frédéric Peyrade,
• Roch Houot,
• Khê Hoang-Xuan,
• Hervé Ghesquieres,
• Carole Soussain

Affiliations

Marion Alcantara

CellAction, Center for Cancer Immunotherapy, Institut Curie

Marion Chevrier

Department of Biostatistics, Institut Curie

Fabrice Jardin

Department of Clinical Hematology and INSERM U1245, Centre Henri Becquerel

Anna Schmitt

Service d’Hématologie, Institut Bergonié

Caroline Houillier

Neurooncology Department, Assistance Publique – Hôpitaux de Paris (APHP), Sorbonne Université, IHU, ICM, Groupe Hospitalier Pitié-Salpêtrière

Lucie Oberic

Hematology, Institut Universitaire du Cancer de Toulouse Oncopôle

Olivier Chinot

AP-HM, Service de Neuro-Oncologie, CHU de la Timone, Aix-Marseille Université, CNRS, INP

Franck Morschhauser

Univ. Lille, CHU Lille, ULR 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées

Frédéric Peyrade

Service d’Onco-hématologie, Centre Hospitalier Simone Veil

Roch Houot

Department of Hematology, University Hospital of Rennes, UMR U1236, INSERM, University of Rennes, French Blood Establishment

Khê Hoang-Xuan

Neurooncology Department, Assistance Publique – Hôpitaux de Paris (APHP), Sorbonne Université, IHU, ICM, Groupe Hospitalier Pitié-Salpêtrière

Hervé Ghesquieres

Department of Hematology, Hôpital Lyon Sud, Claude Bernard Lyon 1 University

Carole Soussain

Clinical Hematology Unit, Institut Curie